197 results about "Pulmonary heart disease" patented technology

The invention discloses a medical combination for treating pulmonary heart disease and rheumatic heart disease and the preparation method thereof; the invention is prepared by peach kernel, safflower, angelica, charles abraham, Szechwan Lovage Rhizome, red peony root, achyranthes root, balloonflower root, bupleurum, citrus aurantium, and licorice. The medical combination of the invention has the efficacy of activating blood, promoting qi and ending pains, mainly for the treatment of pulmonary heart disease, rheumatic heart disease, the chest pain and headache caused by the clotted blood and the unsmooth blood flow in the chest, and also for coronary angina pectoris, chest contusion, rib chondritis chest pain, neurosis, deprementia of the concussion of brain sequela, dizziness headache, and other diseases. The invention has the advantages of simple formula, easy production, convenient taking by the patients, obvious efficacy, and wide application value.

The invention relates to Chinese traditional medicine technology field, it is a Chinese traditional medicine compound for curing pulmonary heart diseases. It includes Chinese herbal medicines lepidium seed, chuanxiong rhizome, its character lies in: the prescription is made up of 1-3 shares of lepidium seed or its extract, 1-2 shares of chuanxiong rhizome or its extract and proper quantity of accessories. Compared with current technology, the medicine reduces the carbon dioxide branch pressure, upgrades the effect of the high oxygen branch pressure, and supplements the blank of Chinese patent medicine injection solution for curing pulmonary heart diseases. It overcomes the deficiencies that the curative effect is low, and the side effect is large and not ideal. The investment is little, and the cost is low.

The invention relates to a healthy tea and preparation method thereof, specially to a healthy tea for treating asthma cough and preparation method thereof. Asthma cough is a common respiratory disease, and the disease can be caused by trachitis, emphysema, pulmonary heart disease, bronchiectasis, pulmonary fibrosis, and pneumoconiosis; the incidence of asthma cough is highest when climate is dry or cold in spring and winter, and the disease is most common in middle-aged and aged people. Taking traditional Chinese medicine theories as a guide and combining with the long-history Chinese tea drink culture, the healthy tea for treating asthma cough of the present invention is elaborately prepared from main materials of tea and honey, and medicinal materials of glycyrrhiza, bamboo leaf, sterculia lychnophora, loquat leaf, rabdosia rubescens, Chinese yam, cinnamon, artemisia capillaries, radix adenophorea, balloonflower, tangerine peel, rhizoma pinelliae, and fritillaria. The healthy tea can effectively improve human immunity, eliminate inflammations in pulmonary tracheae and bronchus, so that treatment effects of dispersing phlegm, dispelling crux, relieving asthma and stopping cough are achieved.

The invention discloses a basidiocarp fungus, and especially relates to a Ceriporia lacerata and application thereof. The preservation number of the Ceriporia lacerata (Ceriporia lacerata N.Maek., Suhara&R.Konda) is CGMCC No.5125; the preservation unit is the China General Microbiological Culture Collection Center (CGMCC); and the preservation date is August 15, 2011. The Ceriporia lacerate provided by the invention can be used for treating anemia, heart disease, phthisis, pulmonary heart disease, lung cancer, myeloma, leukemia and hysteromyoma.

The invention relates to a ginseng stem leaf total sapogenin oral pharmaceutical preparation as well as a preparation method and an application thereof, belonging to the field of traditional Chinese medicines. Total aglycone extracted from ginseng stem leaf is hydrolyzed to obtain ginseng stem leaf total sapogenin, and the ginseng stem leaf total sapogenin is made into an efficient preparation by matching with a special auxiliary material, thereby the bioavailability of the ginseng stem leaf total sapogenin can be greatly improved. The preparation has obvious curative effect in the aspect of curing diseases such as coronary heart disease, stenocardia, miocardial infarction, hepatitis, tumour, pulmonary heart disease, high blood pressure, and the like or the aspect of preventing depressive illness and senile-resistant.

The present invention is one kind of the recipe and preparation process of cardiopulmonary disease treating Chinese medicine composition. The Chinese medicine composition includes main material comprising astragalus root, pepperweed seed, Chuanxiong rhizome and trichosanthes peel, as well as supplementary material. The Chinese medicine composition as one kind of Chinese medicine injection for treating cardiopulmonary disease is superior to available medicines in that it can obviously lower CO2 partial pressure and raise oxygen partial pressure.

The invention discloses a preparation method and a quality control method of a traditional Chinese medicine preparation for treating bronchial asthma, chronic asthmatic bronchitis, emphysema and early pulmonary heart diseases. The preparation method is characterized by being a preparation method of a cough-relieving capsule as a traditional Chinese medicine preparation formed by reforming a cough-relieving tablet, optimization and screening are carried out on an extraction process, and modern new equipment and new method are adopted so as to be suitable for large-scale industrial production; the research on the quality standard is to perfect and improve on the basis of the original standard to establish a perfect method for thin bed identification and content determination so that the quality standard of a product is advanced and controllable, and the clinical effect is ensured.

The invention discloses a medicine for treating cough. The medicine adopts Cortex Mori, Radix Panacis Quinquefolii, Bulbus Fritillariae Unibracteatae, Cordyceps, Radix Scutellariae, Radix Saposhnikoviae, Fructus Forsythiae, Radix Aucklandiae, Cortex Magnoliae Officinalis, Radix Platycodi, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Radix Astragali, Flos Lonicerae, Endothelium Corneum Gigeriae Galli, Rhizoma Atractylodis Macrocephalae, Herba Ephedrae, Poria and Roasted Radix Glycyrrhizae as the raw materials. The drugs are dried, crushed and prepared into power or capsules. The invention is used for treating chronic bronchitis, allelgic asthma, emphysema, pulmonary heart disease and high blood pressure and has the advantages of quick relieving cough, eliminating phlegm and relieving asthma, enhancing appetite, promoting digestion, the most remarkable characteristic of both temporary solution and permanent cure, good long term effect.

The invention relates to a pharmaceutical composition for treating lung diseases, and belongs to the field of traditional Chinese medicines. The drug is an orally administered preparation prepared from medical materials and pharmaceutically common auxiliary materials by a pharmaceutically common process, wherein the medical materials include honeysuckle, nepeta, peucedanum, fried radix cynanchi, almond, fritillaria, red tangerine peel, forsythia, fried stemona, aster, platycodon root, American ginseng, fried lily, reed root, fried ephedra, costazia bone, fructus perillae, fried loquat leaf, fried poppy shell, ledebouriella seseloides, skullcap, gypsum and licorice. Clinical tests prove that the pharmaceutical composition has good treatment effects on emphysema, pulmonary heart disease, asthma, phlegmatic chronic trachitis and other lung diseases.

The present invention relates to a kind of medicine composition, Lemai dripping pill, with functions of activating vital energy, promoting blood circulation, alleviating mental depression, removing blood stasis, nourishing blood and dredging blood vessel and for treating coronary heart disease, atherosclerosis, pulmonary heart disease, infarct dementia, etc. The present invention has high bioavailability, fast medicine release, fast acting, high effective content, taking convenience and low cost, and the production process has no pollution. The Lemai dripping pill is prepared with seven kinds of Chinese medicinal materials, including red sage, Chuanxiong rhizome, red peony root, safflower, etc. and medicine carrier as matrix.

A Chinese medicine in the form of capsule, stable, particle, or oral liquid for treating pulmonary heart disease is prepared from 3 Chinese medicinal materials including astragalus root, red peony root and psoralea fruit through decocting twice (each time for 1 hr.), filtering, concentrating up to relative density of 1.05-1.15 at 80 deg.C, depositing in alcohol standing still for 24 hr, recovering alcohol, continuously concentrating up to relative density of 1.35-1.40 at 80 deg.C concentrating, mixing with red peony root powder, stirring, drying, pulverizing and granulating.

The invention discloses a healthy tea and a preparation method thereof, and in particular relates to a healthy tea for treating old lung disease and a preparation method thereof. Old lung disease is the general term of respiratory diseases, such as chronic bronchitis, emphysema, pulmonary heart disease, bronchiectasis, pulmonary fibrosis, pneumoconiosis and the like. The old lung disease more and more affects the daily life of a patient due to being associated with the symptoms of cough, air deficiency and the like year after year and with the addition of the development of the disease per se. The healthy tea for treating old lung disease is guided by the traditional Chinese medicine theory and is refined from raw materials of honeysuckle, liquorice, scaphium scaphigerum, dried pineapple, loquat leaf, rabdosia rubescens, cinnamon, oriental wormwood, indigowoad root, platycodon grandiflorum, dried orange peel, rhizoma pinellinae praeparata, bulb of fritillary, tea and honey. The healthy tea can effectively improve human body immunity, and eliminate the inflammation of lung trachea and bronchus, thereby achieving the curative effect on removing phlegm and relieving cough.

The invention relates to a high-purity salvianolic acid B and a preparation method and application thereof. The defects of the prior art are that the purity of the obtained salvianolic acid B is lowerthan 92 percent, the steps for obtaining the salvianolic acid B of which the purity is above 92 percent are quite a lot, the cost is very high, and the prior art cannot be applied to industrial production. The preparation method consists of the steps of extraction, pre-column, polyamide chromatography and collection, wherein the pre-column comprises the following steps: filtering an extracting solution and then putting the same on a DA-201 type polar resin column, and using water to remove impurities firstly; then using low-concentration lower alcohol with 1 to 5 carbon atoms to remove the impurities; using the lower alcohol with 1 to 5 carbon atoms to perform desorption; collecting the components containing the salvianolic acid B section by section; and performing decompression and concentration. The salvianolic acid B is applied to the medicaments for treating cardiovascular and cerebrovascular diseases, kidney diseases, pneumonia, pulmonary heart diseases, pancreatitis, diabetes, cervical spondylosis, retinal vascular diseases, retinal nerve diseases, migraine headaches, chronic gastritis, dizziness, bone diseases, and Alzheimer's diseases.

The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Dipyridamole and total glycosides of codonopsis pilosula are employed in combination to obtain various dose forms of injections and oral administration preparations. The composite preparation is mainly used for treating coronary disease, pulmonary heart disease, cerebral ischemia, nervous prostration, climacteric metancholia, The preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, improved curative effect, wider range of safely, and less fluctuation of treatment effects.

The present invention is the application of white flower red sage in preparing medicine and the preparation process of white flower red sage medicine. White flower red sage has danshensu content as high as 2 times that of purple flower red sage, and danshensu is the main effective component for treating cardiac and cerebral vascular diseases and other relevant diseases, and possesses the functions of promoting blood circulation to disperse blood clots, relieving pain, dredging meridian and clearing away heart fire. The white flower red sage medicine has high curative effect on various cardiac and cerebral vascular diseases, and may be also used in treating pulmonary heart disease, viral myocarditis, hypertension, etc.

The invention discloses a medicament for treating cough and asthma diseases, and relates to a Chinese medicament. The medicament is prepared from the following raw materials: 20 to 40 grams of remote lemongrass herb, 5 to 25 grams of Chinese angelica, 5 to 25 grams of white paeony root, 5 to 25 grams of apricot kernel, 8 to 25 grams of platycodon root, 3 to 18 grams of fine-leaf schizonepeta herb, 3 to 18 grams of divaricate saposhnikovia root, 3 to 18 grams of skullcap root, 3 to 18 grams of mint, 3 to 18 grams of tatarian aster root, 3 to 18 grams of dried orange peel, 3 to 18 grams of cassia twig, 3 to 18 grams of liquorice root, 3 to 15 grams of dried ginger, 4 to 8 grams of dahurian angelica root and 2 to 6 grams of ephedra root; and during preparation, the ground powder is mixed to prepare powder or capsules. The medicament has the advantages of simple formula, low cost, no pain, quick response and high curative effect, is easy to produce and convenient to use, and is a good medicament for treating acute and chronic bronchitis, bronchial asthma, pulmonary emphysema and pulmonary heart disease.

The invention provides a Chinese traditional medical preparation for curing the pulmonary heart disease, which is composed of following components: danshen root 10 to 15g, red peony root 7 to 10g, almond 10 to 15g, astragalus root 15 to 30g, lumbricus 7 to 10g, officinal magnolia 7 to 10g, immature bitter orange 10 to 15g, baical skullcap Root 10 to 15g, indian buead 10 to 20g, szechuan lovage rhizome 10 to 15g, towel gourd vegetable sponge10 to15g, schisandra fruit 10 to 15g, liquorice7 to 10g, Chinese ephedra 5 to10g and ginseng 5 to 10g; the prescription has effects of regulating qi and resolving phlegm, clearing heat and relieving dyspnea, and promoting blood circulation by removing blood stasis; so as to cure the pulmonary heart disease caused by various factors.

The invention relates to application of an artemisia leaf extract, and in particular relates to application of an artemisia leaf extract in a medicament for treating pulmonary heart diseases and a preparation method of the artemisia leaf extract. The invention discloses the application of the artemisia leaf extract in preparing the medicament for treating the pulmonary heart diseases. The pulmonary heart diseases have the characteristics of high epidemicity, high morbidity rate, high death rate and high cost, and surveys show that the morbidity rate of people living in rural areas in northern China is 0.44%, therefore, the development of a pulmonary heart disease Chinese traditional medicine treatment medicament with a definite curative effect, a reasonable cost and sufficient supply of goods is of great significance. Meanwhile, the traditional Chinese medicament namely artemisia leaf is further developed and studied, and is finally pushed to the market, which also is one of important paths of realizing modernization of Chinese medicaments.

The invention relates to a medicine [Xiaoling (in pinyin) Soup 12#] for treating tracheitis, rhinitis, pharyngitis, pneumonectasis, pulmonary heart diseases and asthmatic diseases, which comprises ganoderma, ginseng, herba epimedii, radix astragali, giant knotweed, rhizoma gastrodiae, herba houttuyniae and liquorice. The medicine for treating the tracheitis, the rhinitis, the pharyngitis,the pneumonectasis, the pulmonary heart diseases and the asthmatic diseases is made of pure traditional Chinese medicines and has numerous advantages of good curative effect, small side effect, short course of treatment, and the like; at the same time, the formula of the medicine can be simultaneously used for treating a plurality of diseases, has the effects of being antibacterial and antiphlogistic, relieving a cough, stopping asthma, decreasing blood pressure and blood sugar, calming, soothing nerves, promoting blood circulation, alleviating pain, killing viruses and improving the immunity of a human body, and further has the actions of treating tumors, pronging life and preventing ageing. The medicine has the characteristics of quick effect and high cure rate for the treatment of bronchitis, bronchiectasis, allergic rhinitis, nasosinusitis, the pharyngitis, the pneumonectasis, the pulmonary heart diseases and the asthmatic diseases.

The invention discloses a tanshinone IIA phosphoric acid derivative and synthesis and use thereof as a medicine for treatment. In particular, the present invention provides a novel derivative shown as a general formula (I) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the novel derivative shown as the general formula (I), and a method for preparing the novel derivative shown as the general formula (I). The invention also discloses use of the novel derivative, the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative in preparation of medicines for treatment of coronary heart disease, angina, myocardial infarction, viral myocarditis, arrhythmia, cerebrovascular disease, hepatitis, pulmonary heart disease, bronchial asthma, cancer, kidney disease, eye disease, thromboangiitis obliterans, hypertension, fractures, burns, surgical operations or behcet ' s syndrome. On the basis of ensurance of the activity of tanshinone IIA, the novel derivative, the water solubility of the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative can be improved. Compared with tanshinone IIA sodium sulfonate, the stability is improved, and because the acidity of the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative is reduced obviously, injection stimulation can be avoided. All substituents of the general formula (I) are as defined in the specification.

The invention discloses a traditional Chinese medicine composition and application thereof in the preparation of a drug for treating chronic obstructive pulmonary disease. The traditional Chinese medicine composition is prepared from the following raw materials in part by weight: 1 part of herba epimedii, 1-5 parts of radix codonopsitis, 1-5 parts of radix astragali, 1-5 parts of radix salviae miltiorrhizae, 1-5 parts of radix angelicae sinensis, 1-5 parts of radix rehmanniae preparata, 1-5 parts of radix ophiopogonis, 1-5 parts of pheretima aspergillum, 1-5 parts of radix platycodi and 1-5 parts of radix glycyrrhizae. According to the invention, the traditional Chinese medicine composition can effectively prevent pulmonary angiogenesis and remodeling and effectively reduce airway remodeling; the long-term clinical experience proves that the traditional Chinese medicine composition has good effects of preventing cough, eliminating phlegm, resisting inflammation, preventing emphysema and pulmonary heart disease, improving physical fitness and quality of life, and has no throat discomfort, hoarseness, oropharyngeal candidiasis, rash, contact dermatitis and other side effects.

The invention relates to an ambroxol hydrochloride solution for inhalation and a preparation method thereof. Ambroxol hydrochloride is used as an active ingredient. The ambroxol hydrochloride solution belongs to a sterile inhalation preparation capable of being used for treating diseases such as bronchial asthma, chronic bronchitis, emphysema, pulmonary heart diseases, pulmonary infection and COPD (chronic obstructive pulmonary diseases).

The invention relates to a health care food, and in particular relates to a fruit and vegetable heart nourishing tea and a preparation method of the tea. The fruit and vegetable heart nourishing tea comprises pueraria flavone, seabuckthorn flavone, ginkgo flavone, soy isoflavone, coenzyme Q10, red ginseng, salviae miltiorrhizae, rhizoma alismatis, radix astragali, malt, blueberries, barbary wolfberry fruit and the like, and is prepared by grinding the cytoplasm of the raw materials in an ultrasonic way to obtain irregular granules. The fruit and vegetable heart nourishing tea can be used for the adjuvant therapy of various heart diseases in a way of dietary therapy, aims at the people with coronary heart disease, pulmonary heart disease, rheumatic heart disease, myocarditis, hypertension, hyperglycemia, hyperlipidemia, diabetes mellitus and the like, is strong in activity and high in cure rate, and enables the diseases not to easily relapse after the diseases are cured.

The invention discloses fritillaria superfine powder as well as a preparation method and application thereof. The preparation method comprises the following steps: step 1, selecting materials and cleaning; step 2, drying and sterilizing; step 3, grinding and pulping; step 4, pre-freezing slurry; step 5, freezing and drying; step 6, smashing for multiple times into the fritillaria superfine powder with a grain size of 0.5-2 [mu]m. The fritillaria superfine powder is prepared by the preparation method. The fritillaria superfine powder prepared by the preparation method is taken as an only active ingredient to be applied to the preparation of a drug for treating a pulmonary disease. The fritillaria superfine powder disclosed by the invention is used for treating pneumothorax, pulmonary bullous, emphysema, pulmonary shadow, lung cancer, pulmonary heart disease, respiratory failure, pulmonary embolism, pulmonary abscess, pneumonia, neonatal pneumonia, infantile pneumonia, trachitis, asthma, pulmonary tuberculosis, pneumoconiosis and / or interstitial lung disease and has the advantages that the treatment effect is obvious, the condition of a patient is stable, the life quality of the patient is improved, the weight of the patient is increased, the immune function of the patient is improved, and the medication is safe.

The invention discloses a traditional Chinese medicine combination used for curing heart disease, which is characterized in that the invention is prepared by the following compositions in portions by weight: 60-100 portions of rehmanniae vaporata, 30-50 portions of Chinese yam rhizome, 30-50 portions of common macrocarpium, 13-18 portions of cortex moutan, 13-18 portions of China root green birer rhizome, 13-18 portions of alisma orientale, 8-12 portions of cassia bark, 2-5 portions of hairy antler, 2-5 portions of tortoise plastron, 1-3 portions of schisandra chinensis and 1 portion of amomum villosum powder. The invention essentially cures coronary heart disease, pulmonary heart disease, rheumatic heart disease as well as hypertensive heart disease and congenital heart disease; the invention reaches 100 percent efficiency and 95 percent cure rate within one year when the heart disease attacks; symptoms of 5 percent of aged patients and patients who have two long duration of disease and systemic failure can be promoted, thus prolonging life-span.

The invention discloses a lung-clearing asthma-relieving phlegm-reducing Chinese patent drug comprising the following components in parts by weight: 10-20 affine cudweed, 10-20 geranium wilfordii, 20-40 golden buckwheat rhizome, 5-15 fructus persicae immaturus, 10-20 isatis roots, 5-15 liquorice, 5-15 radix stemonae, 5-15 shizandra berries, 10-20 scrophularia ningpoensis, 20-40 concha ostreae and10-30 fructus trichosanthis. A preparation method of the lung-clearing asthma-relieving phlegm-reducing Chinese patent drug comprises the following steps of: (1) firstly coarsely crushing the components, and then uniformly mixing; (2) finely crushing to a grain diameter of less than 5 mum, and carrying out micropowder crystallization. The lung-clearing asthma-relieving phlegm-reducing Chinese patent drug can generate the pharmacological effects of clearing lung heat, resisting bacteria and inflammation, relieving coughs, eliminating phlegm, relieving asthma, nourishing yin, moistening lung, tonifying qi, and the like through the mixed and synergetic effects of the effective components of Chinese medicinal herbs and has good effects on respiratory system diseases, i.e. bronchial asthma, acute and chronic bronchitis, pneumonia, emphysema, pleural effusion, pulmonary heart diseases, chronic pharyngolaryngitis, difficult sleeping due to night cough, and the like after being taken.

The invention relates to a Chinese traditional medicine for treating asthma. The invention is characterized in that the medicine contains the raw materials with the following weight proportions: Radix Scutellariae 10-35, Radix Stemonae 5-35, Radix Asparagi 5-25, Cortex Lycii 5-25, Radix Ophiopogonis 8-25, Folium Pyrrosiae 10-30 and Radix Glycyrrhizae 8-20. The Chinese traditional medicine for treating asthma has the effects of relieving cough and asthma, eliminating phlegm, clearing away the lung-heat, soothing the liver and invigorating the kidney. The medicine of the same kind, such as the ophylline sustained release tablets and the compound clorprenaline Bisolvon tablets, have bigger side effects and quite a few contraindications and can only achieve temporary solution and not permanent cure. The medicine of the invention has the advantages of both temporary solution and permanent cure, evident effect and no side effects. The invention is applicable for treating acute and chronic bronchitis, bronchial asthma and pulmonary heart diseases. Years of treated cases show that the medicine of the invention has 98 percent of effective rate and 92 percent of cure rate on asthma.

The invention relates to a traditional Chinese medicine preparation for curing cough and asthma, which belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine preparation is characterized by being prepared by the following traditional Chinese medicines according to the weight percentage: 70g of sichuan fritillary bulb, 100g of liquorice, 50g of tabasheer, 5g of cinnabar, 1g of Chinese ephedra, 50g of cnidium fruit, 50g of coltsfoot flower and 100g of pinellia tuber; and the medicines are accurately weighed according to a medical prescription, cleanly selected, respectively ground into fine powder, extremely ground into delicate powder, sieved with 120 meshes and then put up in capsules after sterilization. The traditional Chinese medicine preparation for curing cough and asthma can be used for various coughs and asthmas, has the effects of reducing sputum, relieving cough and relieving asthma, has special effects for curing acute and chronic trachitis, bronchitls, emphysema, pulmonary heart disease and cough and asthma and has the characteristics of short treatment course, fast effect and high curative ratio. After the statistics on clinical therapeutic effects to 500 patients, the total effective rate can reach 98 percent and the curative ratio is up to over 80 percent.

The invention belongs to the field of Chinese medicaments for treating heart diseases, and provides a Chinese medicament for treating pulmonary heart disease aiming at good curative effect and quick response. The Chinese medicament is prepared from Chinese ephedra, semen plantaginis, panax pseudoginseng, almond, glossy ganoderma, rhizoma imperatae, angelica, magnolia officinalis, dried orange peel and other Chinese medicaments, and has the functions of supporting body resistance and consolidating constitution, clearing heat and nourishing the lung, promoting blood circulation by removing blood stasis. The Chinese medicament has the advantages of good effect, quick response, significant effect, definite drug effect and quick response.

The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Troxerutin and one or two of ligustilides and Ligusticum wallichii alkaloids are employed in combination to obtain various dose forms of injections and oral administration preparations. The composite preparation is mainly used for treating coronary disease, angina pectoris, cerebrovascular disease, pulmonary heart disease, thrombotic phlebitis, capillary vessel hemorrhage and hypertension.